Top Markets
#1 Palladium Network Palladium Network +27.92%
#2 Siren Siren +24.82%
#3 Ankr Network Ankr Network +20.98%
#4 BankrCoin BankrCoin +19.15%
#5 Status Status +12.73%
#6 Hive Hive +11.15%
#7 Pons Pons +9.35%
#8 Provenance Blockchain Provenance Blockchain +9.19%
#9 Prom Prom +8.82%
#10 Useless Coin Useless Coin +8.39%
Coin of the day
Palladium Network Palladium Network
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Voyager Therapeutics, Inc. Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc.

VYGR
Classifica tra le azioni #18069
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating... Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Prezzo delle azioni
$3.54
Ultima sincronizzazione: 2026-09-02
Capitalizzazione di mercato
$213.59M
Variazione (1 giorno)
3.06%
Variazione (1 anno)
-3.94%
Paese
US
Scambia Voyager Therapeutics, Inc. (VYGR)

Categoria

Healthcare
Utile per Voyager Therapeutics, Inc. (VYGR)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Voyager Therapeutics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Voyager Therapeutics, Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH